Q32 Bio | 8-K: Q32 Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Q32 Bio | 8-K: Current report
Q32 Bio | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Q32 Bio | 8-K: Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
Q32 Bio | S-1: General form for registration of securities under the Securities Act of 1933
Q32 Bio | 8-K: Current report
Homology Medicines | 8-K/A: Current report (Amendment)
Homology Medicines | 8-K: Current report
Homology Medicines | 8-K: Current report
Homology Medicines | 8-K: Current report
Homology Medicines | 8-K: Current report
Homology Medicines | 8-K: Current report
Homology Medicines | 8-K: Current report
Homology Medicines | 8-K: Current report
Homology Medicines | 8-K: Current report
Homology Medicines | 8-K: Current report
Homology Medicines | 8-K: Current report
Homology Medicines | DEFA14A: Others
Homology Medicines | DEF 14A: Definitive proxy statements
Homology Medicines | S-3: Registration statement for specified transactions by certain issuers
No Data
No Data